LAT and non-small cell lung carcinoma: Additionally, two single-arm phase II trials (NCT02759835, NCT04216121) are ongoing to evaluate the efficacy of osimertinib combined with LAT in patients with EGFR-mutated Oligo-PD NSCLC.